Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.60 |
| ▸ | CA2 | P00918 | 5/20 | 0.60 |
| ▸ | CA12 | O43570 | 4/20 | 0.60 |
| ▸ | CA7 | P43166 | 4/20 | 0.60 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.50 |
| ▸ | APOB | P04114 | 1/20 | 0.42 |
| ▸ | MTTP | P55157 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11452204 | 0.89 | CA1 (0.58) | CA1CA2CA12CA7CA14 | |
| SCHEMBL27800978 | 0.83 | CA1 (0.54) | CA1CA2CA12CA7CA14 | |
| SCHEMBL5016614 | 0.82 | CA1 (0.46) | CA1CA2CA12CA7CA14 | |
| SCHEMBL9505624 | 0.80 | CA1 (0.63) | CA1CA2CA12CA7CA14 | |
| SCHEMBL6583483 | 0.79 | CA1 (0.64) | CA1CA2CA12CA7CA14 | |
| SCHEMBL8008813 | 0.79 | CA1 (0.64) | CA1CA2CA12CA7CA14 | |
| SCHEMBL3858010 | 0.79 | CA1 (0.61) | CA1CA2CA12CA7CA14 | |
| SCHEMBL11444221 | 0.79 | CA1 (0.61) | CA1CA2CA12CA7CA14 | |
| SCHEMBL31637765 | 0.79 | CA1 (0.61) | CA1CA2CA12CA7CA14 | |
| SCHEMBL4808483 | 0.79 | CA1 (0.61) | CA1CA2CA12CA7CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | ZHAN-PLASKET FAN | 2009-12-31 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326258-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRALIN AND SUBSTITUTED INDANE DERIVATIVES | TDO2, ITPA, TTI2 | CA1 1674/4885CA2 2963/4885CA12 1638/4885 |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | TDO2, ITPA, TTI2 | CA1 1674/4885CA2 2963/4885CA12 1638/4885 |
| US-20050240049-A1 | Process for the preparation of substituted tetralin and substituted indane derivatives | TDO2, TTI2, ITPA | CA1 1595/4885CA2 2880/4885CA12 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.